Clinical Trial

Treatment of Nosebleeds in the Emergency Department With Powder Tranexamic Acid

Study acronym: Bloody SIMPLE
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated May 30, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
Nosebleeds are very common, occurring in 60% of the population; in some patients, nosebleeds are a life-threatening emergency. To stop a nosebleed in the emergency department, doctors usually have to burn the nose (called cauterization) or insert pledgets (called nasal packing) into the nose to apply direct pressure to the bleeding site. Nasal packing can cause pain and discomfort at the time it is inserted in the nose and again when it is removed. In rare cases it can cause a range of complications: minor complications include scar bands in the nose, but serious complications of nasal packing have also occurred, including death. Nasal packing can also present risks to doctors, such as the risk of contracting airborne and bloodborne infections, like COVID-19 and HIV. Tranexamic acid in pill form or given directly into a vein is a medication that is currently used for nosebleeds. This study looks to evaluate if tranexamic acid in powder form sprayed directly in the nose can be used as an alternative to cauterization or nasal packing for the treatment of nosebleeds.
Trial Details
NCT Number NCT06997796
Lead Sponsor Dr. Anne Conlin
Collaborators: University of Ottawa
Conditions Epistaxis Nosebleed
Enrollment 24 participants
Start Date 2025-05
Primary Completion 2025-12 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2025-05-30